FILE:MYL/MYL-8K-20101115172529.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
o
      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
o
 
 
 
Item 8.01. Other Events.
     On November 15, 2010, Mylan Inc. (the "Company") issued a press release announcing the completion of the conversion of 2,139,000 shares of the Company's 6.50% Mandatory Convertible Preferred Stock (the "Preferred Stock") into 125,234,172 of the Company's common stock. As previously announced, the conversion rate was fixed at one share of Preferred Stock for 58.5480 shares of Mylan common stock.
     A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
     (d) Exhibits.
 
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

Exhibit 99.1
PITTSBURGHNov. 15, 2010Mylan Inc. (Nasdaq: MYL) today announced the completion of the conversion of 2,139,000 shares of the company's 6.50% Mandatory Convertible Preferred Stock (the "Preferred Stock") into 125,234,172 shares of the company's common stock. As previously announced, each share converted into 58.5480 shares of common stock, the minimum conversion ratio permitted by the Articles of Incorporation, reflecting strong stock performance since the preferred stock was issued. After accounting for this conversion, the total number of common shares stands at 435,218,767, based upon the number of common shares outstanding as of November 12, 2010. These shares were included in the company's forecasted results under the "if converted method."
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


